A New Shot at Progress: Amivantamab Goes SubQ

Catalog

VIKTOR

Podcast | English | 2025 | 35 Min

Create Account

Cost

$0.00

Credit

No Credit Offered

This episode of Lung Cancer Considered breaks down the FDA approval of subcutaneous amivantamab. Join host Dr. Narjust Florez and guests, Dr. Natasha Leighl and Dr. Federico Cappuzzo, as they explore the science and convenience factor, as well as what this shift means for patients, clinicians, and oncology practice.

Podcast Hosts:

Narjust Florez, MD, Associate Director of the Cancer Care Equity Program and Thoracic Medical Oncologist, Dana-Farber Cancer Institute; Assistant Professor of Medicine, Harvard Medical School, Boston, MA, USA

Podcast Guests:

Frederico Cappuzzo, MD, Director of Medical Oncology, National Cancer Institute Regina Elena in Rome, AUSL della Romagna, Ravenna, Italy
Natasha Leighl, MD, FASCO, Thoracic Medical Oncology Group Lead, Princess Margaret Cancer Centre, Toronto, Canada